Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Willis Tower Watson in its divestment of Max Matthiessen
Mandate

Vinge advises Willis Tower Watson in its divestment of Max Matthiessen

May 25, 2020 Banking and Finance EU, Competition and Regulatory M&A Insurance Law Corporate Tax

Vinge advises Willis Tower Watson, global risk adviser, insurance and reinsurance broker, in its divestment of Max Matthiessen to Nordic Capital.

Max Matthiessen was founded 1889 and as active in insurance brokerage and financial advisory services for companies and individuals. The company has 440 employees at approximately 30 locations throughout Sweden with headquarter in Stockholm. In 2019, Max Matthiessen had a customer base of around 13,000 clients with revenues exceeding SEK 1.5 billion. Willis Tower Watson acquired Max Matthiessen from Altor 2014.

The acquisition is conditional upon customary regulatory approvals and conditions to closing.

Vinge’s team consisted of, amongst others, Peter Sundgren, Joacim Rydergård, Stina Bengtsson and Olivia Belding (M&A), Fabian Ekeblad and Paulina Malmberg (Regulatory Insurance), Albert Wållgren (Banking & Finance), Maria Schultzberg (Tax), Xandra Ståhlberg (Competition law) and Nathalie Hughes (VDR-assistant).

 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026